Marathon Capital Management Has $4.21 Million Stock Position in Novo Nordisk A/S $NVO

Key Points

• Marathon Capital Management increased its Novo Nordisk stake by 43.9% in Q4 and now owns 82,705 shares valued at about $4.21 million.
• Novo Nordisk beat Q4 estimates with $1.01 EPS vs. $0.90 expected and $12.43 billion in revenue, and the company shows strong profitability (net margin 33.03%) with a market cap of $183.93 billion.
• Positive news that oral semaglutide met its main goal in a late‑stage pediatric trial has lifted shares and reinforced Novo’s position in obesity drugs, though analysts remain cautious overall with a consensus "Hold" rating and a $65.56 price target amid valuation concerns.

Marathon Capital Management lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 82,705 shares of the company's stock after purchasing an additional 25,230 shares during the quarter. Marathon Capital Management's holdings in Novo Nordisk A/S were worth $4,208,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Capital International Investors grew its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company's stock worth $982,969,000 after purchasing an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. boosted its stake in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company's stock valued at $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Folketrygdfondet boosted its stake in Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company's stock valued at $566,659,000 after buying an additional 117,370 shares in the last quarter. State Street Corp boosted its stake in Novo Nordisk A/S by 1.0% in the third quarter. State Street Corp now owns 6,106,836 shares of the company's stock valued at $340,125,000 after buying an additional 59,153 shares in the last quarter. Finally, Boston Partners acquired a new stake in Novo Nordisk A/S in the third quarter valued at about $310,199,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $41.19 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $183.93 billion, a PE ratio of 11.87, a P/E/G ratio of 9.17 and a beta of 0.73. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The stock has a 50-day moving average price of $39.13 and a two-hundred day moving average price of $47.81.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Analysts expect that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a $1.2751 dividend. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 50.43%.

Analyst Ratings Changes

Several analysts recently weighed in on NVO shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an "outperform" rating and a $73.50 price objective on the stock. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price target for the company. Finally, Morgan Stanley upgraded Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial win — oral semaglutide met its main goal in 10–17 year olds with type 2 diabetes, supporting a planned U.S. launch and expanding addressable market for an oral GLP‑1 in youth. Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Market reaction to trial news — outlets report NVO shares rising after the pediatric oral semaglutide data, indicating investor enthusiasm for incremental product launches and revenue growth. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Positive Sentiment: Competitive edge in obesity market — early prescription data show Lilly’s new obesity treatment trailing Novo’s Wegovy, pressuring Lilly shares and reinforcing Novo’s market leadership in weight‑loss drugs. Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
• Positive Sentiment: Short interest fell sharply — short interest declined ~14.6% in April to ~17.0M shares (0.4% of float), lowering potential short‑squeeze risk and signaling reduced bearish positioning. (internal short‑interest data)
• Neutral Sentiment: Valuation/price discussion — analysts and commentators are parsing whether current pricing reflects recent share weakness and longer‑term growth prospects; this keeps the stock sensitive to further data and guidance. Is Novo Nordisk NYSE: NVO Pricing Reflect Its Recent Share Slump And Growth Outlook
• Negative Sentiment: Analyst target trimmed — Citigroup cut its price target (DKK 309 → DKK 275) while keeping a neutral rating, a reminder of lingering valuation concerns that could cap upside. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Recent short‑term pullbacks — coverage noted a recent session where NVO closed lower, highlighting that momentum can reverse on macro or sector weakness. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.